RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
AI-Ultrasound RET Prediction: Deep-learning algorithm that analyses thyroid ultrasound DICOM images and outputs a probability score for RET gene alteration and lateral-neck lymph-node metastasis; run offline, results blinded to treating surgeons.
Study summary
Why is this study being done? RET gene alterations occur in only 5-10 % of papillary thyroid cancers, but they can change how surgeons treat the disease. Gene testing is costly and not always performed, so many RET-positive tumours are missed. Researchers have built a computer program (artificial-intelligence or "AI" model) that reads routine thyroid ultrasound images and predicts whether the tumour carries a RET alteration and whether the cancer has already spread to lymph-nodes in the side of the neck.
What will happen in this study?
About 800 adults who are scheduled for thyroid-cancer surgery will take part. Each participant will:
* have a standard pre-operative ultrasound exam (no extra scanning time),
* give a routine fine-needle sample for a 14-gene panel test (results in 24 h), and
* allow the AI model to analyse the ultrasound images in the background. Doctors making treatment decisions will not see the AI result. After surgery, the research team will compare the AI predictions with the gene-panel result and the final pathology report.
Main goal: To find out how accurately the AI model detects RET alterations. Secondary goals: To measure the model's ability to predict lymph-node spread, and to compare costs between ultrasound-only prediction and full gene testing.
Benefits and risks: Participants will receive the current standard of care; there is no added risk beyond the usual ultrasound and needle biopsy. The study could lead to faster, less expensive ways to identify high-risk thyroid cancers in the future.
Eligibility
Primary outcome measure(s)
- Area Under the ROC Curve (AUC) for AI-Ultrasound Detection of RET Alterations — Date of surgery (assessment completed when gene-panel result is available)
The receiver-operating-characteristic area under the curve comparing the AI-generated probability score against the reference 14-gene next-generation sequencing (NGS) result for RET fusion or point mutation. AUC calculated with 95 % confidence interval via DeLong method.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Fujian Medical University Union Hospital | Fuzhou | FJ |
More Fujian Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07042984 on ClinicalTrials.gov ↗ ← All trials in China